fig3

Figure 3. Effect of conventional chemotherapeutic drugs used in NSCLC treatment (paclitaxel, vinorelbine, or carboplatin), alone or in combination with bosutinib or ecF506, on the percentage of cell growth in sensitive NCI-H460 and MDR NCI-H460/R counterpart cell lines, assessed by the SRB assay. Serial dilutions of the chemotherapeutic drugs were applied with or without 0.72 µM bosutinib or 11.74 µM ecF506. The vehicle at the highest tested concentration was used as control. Combinations tested: (A) paclitaxel + bosutinib; (B) vinorelbine + bosutinib; (C) carboplatin + bosutinib; (D) paclitaxel + ecF506; (E) vinorelbine + ecF506; (F) carboplatin + ecF506. Results represent mean ± SEM of at least three independent experiments. NSCLC: Non-small cell lung cancer; MDR: multidrug resistance; SRB: sulforhodamine B; SEM: standard error of the mean.